Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss

Haven for Hope plans to address ‘critical infrastructure’ needs with ARPA funding2 hours agoTrick or Treat: What candy is best to eat?Looking to save on items for your home, road trip and wardrobe? We've got the latest Insider Deals to share!Read full article: Cozy up this fall with tabletop fire pit and more Insider Deals

Read full article: The key to all-in-one holiday shopping: this Costco Gold Star Membership that comes with a $40 Digital Costco Shop Card*FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. after raising that forecastSales of Lilly's diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built up in previous quarters.

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just getting started in commercializing obesity products globally.”

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings missEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker on Wednesday chopped a few dollars off its earnings guidance for the year after raising that forecast well beyond analyst expectations in previous quarters.
مصدر: AP - 🏆 728. / 51 اقرأ أكثر »

Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings missEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.
مصدر: wjxt4 - 🏆 246. / 63 اقرأ أكثر »